logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > Chemical Intermediates > Loteprednol Etabonate CAS 82034-46-6

Loteprednol Etabonate CAS 82034-46-6

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 82034-46-6

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:
Appearance::
White To Beige Powder
CAS NO::
82034-46-6
Molecular Formula::
C24H31ClO7
Molecular Weight::
466.95200
EINECS NO::
639-474-4
MDL NO::
MFCD00870765
Appearance::
White To Beige Powder
CAS NO::
82034-46-6
Molecular Formula::
C24H31ClO7
Molecular Weight::
466.95200
EINECS NO::
639-474-4
MDL NO::
MFCD00870765
Loteprednol Etabonate CAS 82034-46-6

Product Description:

Product Name: Loteprednol etabonate CAS NO: 82034-46-6


Synonyms:

Loteprednol (INN);

Loteprednolum;


Chemical & Physical Properties:

Appearance: White to beige powder

Assay :≥99.00%

Density: 1.31 g/cm 1.31 g/cm3

Boiling Point: 600.1℃ at 760 mmHg

Melting Point 220.5-223.5℃

Flash Point: 316.7℃

Refractive Index: 1.57

Vapor Pressure: 0.0±3.9 mmHg at 25℃

Storage Condition: Store in original container in a cool dark place.

Solubility: DMSO: soluble5mg/mL, clear (warmed)


Safety Information:

HS Code: 2937229000

WGK Germany: 3


Loteprednol (as the ester loteprednol etabonate) is a corticosteroid used to treat inflammations of the eye. It is marketed by Bausch and Lomb as Lotemax. Loteprednol Etabonate is an anti-inflammatory corticosteroid used in optometry and ophthalmology.IC50 Value:Target: Glucocorticoid Receptorin vitro:in vivo: Intravenous administration of loteprednol etabonate (5 mg/kg) to dogs revealed a terminal half-life of 2.8 h, a volume of distribution of 3.7 L/kg, and a total body clearance of 0.9 L/h/kg. Intact loteprednol etabonate was not detectable in the urine. After oral administration of the drug (5 mg/kg) to dogs, only metabolites, but no intact drug, were found in the plasma, an indication for a high first-pass effect. A pronounced binding of the drug to plasma protein (> 90%) and a high erythrocyte-buffer partition coefficient of 7.8 were determined in vitro.


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.